SEHK:3692Pharmaceuticals
Hansoh Pharmaceutical Group (SEHK:3692) Valuation Update After New NRDL Wins for Ameile, Saint Luolai and Hengmu
Hansoh Pharmaceutical Group (SEHK:3692) just secured fresh National Reimbursement Drug List approvals for new Ameile indications, plus renewals for Saint Luolai and Hengmu, a policy shift that could reshape its revenue mix from 2026.
See our latest analysis for Hansoh Pharmaceutical Group.
That backdrop helps explain why sentiment has swung so hard in Hansoh’s favour, with a 30 day share price return of 18.79 percent and a one year total shareholder return of 137.26 percent signalling strong,...